A Prospective Phase II Clinical Study of Orelabrutinib in Combination With Lenalidomide and Rituximab (OLR) in First-line Treatment of Mantle Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Orelabrutinib (Primary) ; Rituximab (Primary)
Indications Mantle-cell lymphoma
Focus Therapeutic Use
Acronyms POLARIS

14 Jun 2024 Results presented in an InnoCare Pharma Media Release.
14 Jun 2024 According to an InnoCare Pharma media release, results from this trial were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.
12 Dec 2023 Preliminary Results (As of July 10, 2023, n=28) assessing efficacy, safety, and mutation spectrum of OLR regimen in untreated MCL presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com